263 filings
Page 4 of 14
DEF 14A
hubto2xmu y1
26 Jan 21
Definitive proxy
4:49pm
PRE 14A
zgcp4pbhsxswgjgj7v
19 Jan 21
Preliminary proxy
12:00am
EFFECT
x5kfkfwae2tbqk
30 Dec 20
Notice of effectiveness
12:15am
EFFECT
5nfzr6033lu0
30 Dec 20
Notice of effectiveness
12:15am
CORRESP
yck7o
23 Dec 20
Correspondence with SEC
12:00am
CORRESP
scukwq5
23 Dec 20
Correspondence with SEC
12:00am
CORRESP
sfymn
23 Dec 20
Correspondence with SEC
12:00am
CORRESP
xf6yia
23 Dec 20
Correspondence with SEC
12:00am
8-K
yu8ql6k
15 Dec 20
ESSA Pharma Provides Corporate Update and Reports Financial Results for Clinical and Corporate Highlights for 2020 Fiscal Year
5:05pm
10-K
dwsbbzhjrz498v3i g3
15 Dec 20
Annual report
5:02pm
UPLOAD
emycwqzxh9 rfvx
3 Dec 20
Letter from SEC
12:00am
UPLOAD
33au 7i94uk5u
3 Dec 20
Letter from SEC
12:00am
S-3
uj1h30woxn7c788
25 Nov 20
Shelf registration
4:31pm
8-K
1duymvjuooizmz17mv
27 Oct 20
ESSA Pharma Inc. Announces Delisting from the TSX-V
12:00am
6-K
5iop1
21 Sep 20
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
9:40am
6-K
t04wvj7cdz3x6bogqwsj
17 Sep 20
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
5:22pm
6-K
3m2oqx0al6
14 Sep 20
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
9:10am